This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Basal cell carcinoma (BCC)

Protein kinase Ci (PRKCI; aPKC-i/l); sonic hedgehog homolog (SHH)

Studies in vitro, in mice and in human tissue suggest inhibiting PRKCI could help treat SHH-driven BCC. A proteomic screen identified PRKCI as a new component of the SHH signaling pathway. In primary human BCC tumors, levels of total and activated PRKCI were higher than those in healthy human skin samples. In a mouse model for BCC, topical treatment with a peptide inhibitor of PRKCI decreased SHH signaling and tumor growth compared with vehicle treatment. Next steps include screening for more potent and selective peptide or small molecule inhibitors of PRKCI and exploring the effects of PRKCI inhibition in other SHH-driven cancers.

SciBX 6(11); doi:10.1038/scibx.2013.257
Published online March 21, 2013

Patent application filed; available for licensing

Atwood, S.X. et al. Nature; published online Feb. 27, 2013;
doi:10.1038/nature11889
Contact: Anthony E. Oro, Stanford University School of Medicine, Stanford, Calif.
e-mail:
oro@stanford.edu

Contact: Scott X. Atwood, same affiliation as above
e-mail:
satwood@stanford.edu